CG Oncology, Inc. — Form 8-K
Filed November 16, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 78/100
What the filing says
CG Oncology announced positive topline results from PIVOT-006, a Phase 3 trial of cretostimogene in intermediate-risk and high-grade Ta non-muscle invasive bladder cancer (NMIBC). The drug achieved a 68% reduction in recurrence risk (hazard ratio 0.32, 95% CI 0.23–0.45, p<0.0001) versus surveillance in 367 patients, with no Grade 3+ treatment-related adverse events. A second BLA submission for this indication is planned for Q2 2027; the company also plans to expand its first BLA (BCG-unresponsive NMIBC) to include high-grade papillary-only disease, completing submission by March 2027.
Why this rating
Major Phase 3 success in ~$1.7B market-cap company targeting 50K-patient indication. Statistically significant primary endpoint, favorable safety, and expanded label opportunity materially strengthen near-term approval odds and commercial trajectory. High-touch field strategy positioned for concentrated prescriber base.
Tradability signal
NO TRADE
No trade: the filing reads positive but the market is selling it (-12.9% since it hit EDGAR) — when our read and the tape disagree this hard, we stand aside. (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
before filing · preread $98.00 ▲ 9.68% | at our read · unknown $89.35 | +10 min · unknown $83.33 ▼ 6.74% | +30 min · unknown $83.64 ▼ 6.39% | +1 hr · unknown $80.60 ▼ 9.79% | +4 hrs · unknown $85.18 ▼ 4.67% |
The stock had already moved -8.83% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from November 16, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.